menu
    • menu
    [{"orgOrder":0,"company":"Avobis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avobis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Avobis Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avobis Bio \/ Undisclosed"},{"orgOrder":0,"company":"Avobis Bio","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Avobis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Avobis Bio \/ Alimentiv","highestDevelopmentStatusID":"8","companyTruncated":"Avobis Bio \/ Alimentiv"},{"orgOrder":0,"company":"Avobis Bio","sponsor":"Alimentiv","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AVB-114","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avobis Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avobis Bio \/ Alimentiv","highestDevelopmentStatusID":"1","companyTruncated":"Avobis Bio \/ Alimentiv"}]

    Find Clinical Drug Pipeline Developments & Deals by Avobis Bio

    Menu

    Avobis Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avobis Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Avobis Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-114

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avobis Bio Gets FDA Fast Track for AVB-114 Cell Therapy in Crohn’s Fistulas

                            Details : AVB-114 is the company's lead therapeutic candidate, an implantable cell therapy, which is currently being evaluated for the treatment of crohn's perianal fistulas.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 27, 2025

                            Lead Product(s) : AVB-114

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avobis Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Avobis Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-114

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Alimentiv

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expanded Access Protocol for STOMP-II Patients Who Were Unable to Receive Treatment Subsequent to Adipose Tiss...

                            Details : AVB-114 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Perianal Fistula-associated with Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 19, 2024

                            Lead Product(s) : AVB-114

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Alimentiv

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avobis Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Avobis Bio

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVB-114

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Alimentiv

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)

                            Details : AVB-114 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rectal Fistula.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 19, 2021

                            Lead Product(s) : AVB-114

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Alimentiv

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth